Subsequent Pulmonary Resection for Bronchogenic Carcinoma After Pneumonectomy
|
|
- Gerald Kenneth Boone
- 5 years ago
- Views:
Transcription
1 ORIGINAL ARTICLES: GENERAL THORACIC Subsequent Pulmonary Resection for Bronchogenic Carcinoma After Pneumonectomy Jessica S. Donington, MD, Daniel L. Miller, MD, Charles C. Rowland, BS, Claude Deschamps, MD, Mark S. Allen, MD, Victor F. Trastek, MD, and Peter C. Pairolero, MD Division of General Thoracic Surgery and the Section of Biostatistics, Mayo Clinic and Mayo Foundation, Rochester, Minnesota Background. Patients who have undergone a pneumonectomy for bronchogenic carcinoma are at risk of cancer in the contralateral lung. Little information exists regarding the outcome of subsequent lung operation for lung cancer after pneumonectomy. Methods. The records of all patients who underwent lung resection after pneumonectomy for lung cancer from January 1980 through July 2001 were reviewed. Results. There were 24 patients (18 men and 6 women). Median age was 64 years (range, 43 to 84 years). Median preoperative forced expiratory volume in 1 second was 1.47 L (range, 0.66 to 2.55 L). Subsequent pulmonary resection was performed 2 to 213 months after pneumonectomy (median, 23 months). Wedge excision was performed in 20 patients, segmentectomy in 3, and lobectomy in 1. Diagnosis was a metachronous lung cancer in 14 patients and metastatic lung cancer in 10. Complications occurred in 11 patients (44.0%), and 2 died (operative mortality, 8.3%). Median hospitalization was 7 days (range, 2 to 72 days). Follow-up was complete in all patients and ranged between 6 and 140 months (median, 37 months). Overall 1-, 3-, and 5-year survivals were 87%, 61%, and 40%, respectively. Five-year survival of patients undergoing resection for a metachronous lung cancer (50%) was better than the survival of patients who underwent resection for metastatic cancer (14%; p 0.14). Five-year survival after a solitary wedge excision was 46% compared with 25% after a more extensive resection (p 0.54). Conclusions. Limited pulmonary resection of the contralateral lung after pneumonectomy is associated with acceptable morbidity and mortality. Long-term survival is possible, especially in patients with a metachronous cancer. Solitary wedge excision is the treatment of choice. (Ann Thorac Surg 2002;74:154 9) 2002 by The Society of Thoracic Surgeons Patients treated surgically for bronchogenic carcinoma have a 1% to 5% risk per year for development of a second primary lung cancer [1, 2] and a 2% to 5% risk per year of developing recurrent carcinoma, depending on the initial tumor stage [3, 4]. Surgical resection is the preferred treatment for patients who develop a new lung lesion. However, further resection is not always feasible. Difficulty arises when the initial resection was a pneumonectomy. Many physicians consider resection of a lesion in the remaining lung contraindicated. Despite a significant number of pneumonectomies performed annually, few patients actually undergo additional lung resection after pneumonectomy. The information about this select group of patients is limited. The purpose of this review was to analyze our experience of subsequent resection for lung cancer in patients who have had a previous pneumonectomy. Presented at the Thirty-eighth Annual Meeting of The Society of Thoracic Surgeons, Fort Lauderdale, FL, Jan 28 30, Address reprint requests to Dr Miller, Division of General Thoracic Surgery, Mayo Clinic and Mayo Foundation, 200 First St SW, Rochester, MN 55905; miller.danielmd@mayo.edu. Material and Methods Between January 1, 1980 and June 30, 2001, 772 patients underwent pneumonectomy at the Mayo Clinic in Rochester, MN, for lung cancer. Twenty-four (3.1%) of these patients underwent subsequent resection for lung cancer in the contralateral lung. Patients who underwent pulmonary resection for benign disease or other malignancies were excluded. The records of these patients were analyzed for age, sex, preoperative conditions, pulmonary function, initial cell type and postsurgical stage, extent of initial procedure, adjuvant treatment, subsequent tumor cell type and postsurgical stage, type of subsequent resection, morbidity, and mortality. Using criteria previously described by Martini and Melamed [5], new tumors were classified as either metachronous primary lung cancer or metastatic lung cancer. Operative mortality included those patients who died within the first 30 days after operation and those who died later but during the same hospitalization. Survival was estimated by the Kaplan-Meier method using the date of the pulmonary resection after pneumonectomy as the starting point and the date of death or last follow-up as the end point [6]. All statistical tests were two-sided with the threshold of significance set at p less 2002 by The Society of Thoracic Surgeons /02/$22.00 Published by Elsevier Science Inc PII S (02)
2 Ann Thorac Surg DONINGTON ET AL 2002;74:154 9 PULMONARY RESECTION AFTER PNEUMONECTOMY 155 than All analyses were conducted using SAS (SAS Institute Inc., Cary, NC). The study was granted approval by Mayo Foundation s Institutional Review Board. Results Table 1. Complications Complication No. (%) Respiratory complications 6 (25) Pneumonia 5 (21) Respiratory failure 4 (17) Bronchoscopy 3 (13) Tracheostomy 2 (8) ARDS 1 (4) Prolonged airleak ( 7 days) 1 (4) Cardiac complications 3 (13) Atrial fibrillation 2 (8) Ventricular arrhythmia 1 (4) Chylothorax 2 (8) Wound infection 1 (4) Renal failure 1 (4) Stroke 1 (4) ARDS adult resporatory distress syndrome. There were 24 patients (18 men and 6 women) who underwent 25 subsequent pulmonary resections for lung cancer after pneumonectomy. Median age at the subsequent resection was 64 years and ranged from 43 to 84 years. Twenty-three patients (95.8%) were current or former smokers. Nine patients (37.5%) had a completion pneumonectomy. Twelve patients (50%) had a previous right pneumonectomy. Cell type of the original cancer was squamous cell carcinoma in 10 patients, adenocarcinoma in 8, large cell carcinoma in 2, carcinoid in 2, and bronchoalveolar cell carcinoma and adenosquamous cell carcinoma in 1 patient each. Postsurgical stage of the initial cancer was stage IA in 3 patients, IB in 7, IIA in 3, IIB in 4, IIIB in 3, stage IV in 1, and unknown in 3. The initial pneumonectomy included resection of a portion of the superior vena cava in 2 patients and the diaphragm in 1. Eighteen of the subsequent tumors (72.0%) were found in asymptomatic patients by chest roentgenogram in 15, computed tomography in 2, and sputum cytology in 1. The remaining 7 patients were symptomatic and presented with hemoptysis in 4, cough in 2, and progressive dyspnea in 1. Median forced expiratory volume in 1 second was 1.47 L (range, 0.66 to 2.55 L), median percent predicted forced expiratory volume in 1 second was 48% (range, 29% to 83%), and median diffusion capacity for carbon monoxide was 63% (range, 45% to 98%). No patient was using oxygen before the subsequent resection. Six patients (24.0%) had previous adjuvant therapy that included radiation therapy in 3 and a combination of chemotherapy and radiation in 3. Subsequent pulmonary resection was performed 2 to 213 months (median, 23 months) after pneumonectomy through a posterolateral thoracotomy in all patients. Twenty-five pulmonary resections were performed in the 24 patients. One patient had two separate resections (solitary wedge excision and multiple wedge excisions) for metastatic squamous cell cancer. Fourteen resections were for metachronous lung cancer, and 11 were for metastatic lung cancer. The type of resection performed was a solitary wedge excision in 14 patients, multiple wedge excisions in 7, segmentectomy in 3, and lobectomy in 1. Resection was considered complete in all patients. Cell type was squamous cell carcinoma in 10 patients, adenocarcinoma in 7, large cell in 4, and bronchioalveolar in 4. Fifteen patients (62.5%) had the same cell type as the original lung cancer. Complete lymphadenectomy was performed in 6 patients and lymph node sampling in 7. Metachronous tumors were stage IA in 9 patients and stage IB in 5. There were two operative deaths (8.3%), one caused by a stroke with subsequent multisystem organ failure after a segmentectomy and the other secondary to a ventricular arrhythmia after multiple wedge excisions. Complications occurred in 11 patients (44.0%; Table 1). Twenty patients (80.0%) were extubated immediately after the operation, and 3 patients were extubated the next morning. Two patients required a tracheostomy for prolonged ventilatory support. Median hospitalization was 7 days (range, 4 to 72 days). Six patients (25.0%) required supplemental oxygen at discharge; only 2, however, required supplemental oxygen long-term. Fourteen patients (58.3%) underwent a single wedge excision, and 10 had more extensive resections. No difference in preoperative patient characteristics was observed between patients who had a solitary wedge excision and those patients who had a more extensive resection (Table 2). No operative deaths occurred in the 14 patients who had a solitary wedge excision, but 4 experienced complications (28.6%), 1 of which was respiratory (7.1%). Three patients (21.4%) were discharged on supplemental oxygen. In contrast, 2 of the 10 patients with more extensive resection died (operative mortality, 20.0%), and 7 experienced complications (70.0%), 5 of which were respiratory (50.0%). Three patients (30.0%) were discharged on supplemental oxygen. Median hospitalization in the solitary wedge excision patients was 7 days (range, 4 to 22 days) as compared with 13 days Table 2. Preoperative Data Solitary Wedge Extended Resection p Value Number of patients Age (y, median, range) (61) (61) Tobacco use (%) (79) (82) 0.39 COPD (%) (36) (55) 0.35 Preop FEV 1 (L, median) Cardiac comorbidity (%) (21) (27) 0.73 Preop steroids (%) (14) (0) 0.19 Adjuvant therapy (%) (29) (18) 0.55 COPD chronic obstructive pulmonary disease; FEV 1 forced expiratory volume in 1 second; Preop preoperative.
3 156 DONINGTON ET AL Ann Thorac Surg PULMONARY RESECTION AFTER PNEUMONECTOMY 2002;74:154 9 Table 3. Postoperative Data Value Solitary Wedge Extended Resection p Value Mortality (no. of 0 (0) 2 (18) 0.10 patients, %) Complications 4 (29) 7 (64) 0.08 Respiratory 1 (8) 5 (45) 0.03 complications Length of stay (d, (7) 4 22 (13) median, range) Home oxygen (no. of patients, %) 3 (25) 3 (38) 0.55 (range, 4 to 72 days) for patients with more extensive resections (Table 3). Follow-up was complete in all 22 operative survivors and ranged from 6 to 140 months (median, 37 months). No patients received adjuvant treatment during the follow-up period. Currently, 8 patients are alive. The cause of death in the remaining 14 patients included recurrent lung cancer in 7, other cancers in 2, respiratory failure in 2, other medical causes in 2, and unknown in 1. Overall 1-, 3-, and 5-year survival was 87%, 61%, and 40, respectively (Fig 1). Overall median survival was 39 months. One-, 3-, and 5-year survival after resection for metachronous cancers were 86%, 71%,, and 50%, respectively, as compared with 90%, 41%, and 14%, respectively, for metastatic disease (p 0.14; Fig 2). Median survival for metachronous cancer was 73 months compared with 27 months for recurrent cancer (p 0.14) One-, 3-, and 5-year survival after a solitary wedge excision was 93%, 64%, and 46%, respectively, as compared with 80%, 57%, and 25%, respectively, for a more extensive resection (p 0.54; Fig 3). Median survival for patients undergoing a solitary wedge excision was 59 months compared with 39 months for extended resection patients (p 0.53). Comment Patients with a completely resected bronchogenic carcinoma have a 5% to 10% risk of having a new lung cancer Fig 2. Probability of survival (death of any cause) in 14 patients who underwent resection for metachronous primary lung cancer as compared with the 10 patients who had resection for metastatic lung cancer. Zero time on the abscissa represents the date of thoracotomy (p 0.14). [3] and a 30% to 80% risk of having recurrent disease [2, 4]. This percentage will continue to increase as patient survival improves. Nevertheless, surgical resection for bronchogenic carcinoma of the residual lung after pneumonectomy is rarely reported. Fewer than 100 cases have been published in the literature during the last 35 years [5, 7 14]. Factors limiting surgical intervention in these patients are poor pulmonary reserve, the presence of distant metastasis, and a misconception by many physicians that a previous pneumonectomy is an absolute contraindication for subsequent lung resection. Our results demonstrate that further resection in selected patients can be performed with acceptable morbidity and mortality and good long-term survival. Recurrent lung cancer that develops after successful resection of bronchogenic carcinoma usually occurs early and rarely is found after 5 years [1]. In contrast, a new primary lung cancer can occur at any time after curative resection and occurs at a rate of 1% to 5% per year [1, 3, 8]. There are no definitive criteria to differentiate between a metachronous primary cancer and metastatic disease. According to Martini and Melamed [5], a second Fig 1. Probability of survival (death of any cause) in 24 patients who underwent subsequent resection for recurrent lung cancer after pneumonectomy. Zero time on the abscissa represents the date of thoracotomy. Fig 3. Probability of survival (death of any cause) in 14 patients who underwent a solitary wedge excision as compared with the 10 patients who underwent a more extensive resection. Zero time on the abscissa represents the date of thoracotomy (p 0.54).
4 Ann Thorac Surg DONINGTON ET AL 2002;74:154 9 PULMONARY RESECTION AFTER PNEUMONECTOMY 157 lung tumor in a patient previously operated on for lung cancer should be considered a second primary (metachronous) and not a metastasis when the cell type of the two lesions is different, the time interval between the two lesions exceeds 2 years, and there are no other distant metastases. Accordingly, 14 (58.3%) patients in this series had a metachronous lung cancer. Seventy percent to 80% of patients who have metachronous lung cancers are asymptomatic; these new cancers are usually discovered on surveillance chest roentgenograms [5, 15 17]. Symptoms, if present, usually include cough, hemoptysis, and dyspnea [1, 15, 17]. Because the majority of patients are asymptomatic at the time of diagnosis, a long-term follow-up program of lung cancer patients who undergo successful resection is necessary. However, several recent studies have shown that routine surveillance using conventional diagnostic studies does not impact long-term survival [18 20]. Therefore, it is impossible to recommend an aggressive surveillance program after resection for lung cancer. Also, it is difficult to recommend a surveillance program after resection because there is no standard screening method for detection of new lung cancers in the United States. Hopefully, current ongoing high-resolution computed tomography screening studies may change our philosophy about screening and surveillance [20]. Preoperative workup of a lesion suggestive of a second lung cancer is identical to the workup of the initial cancer. Extensive testing is recommended to determine whether the patient has advanced disease within the chest and or extrathoracic sites. Radiologic evaluation should include standard chest roentgenogram and thoracic and upper abdomen computed tomography. Computed tomography of the brain and a bone scan should be considered in selected patients. As positron emission tomography scans become more available and reliable, they may become the diagnostic tool required before proceeding with resection in patients with recurrent disease. None of our patients had a positron emission tomography scan before subsequent resection. If there is evidence of mediastinal lymphadenopathy, mediastinoscopy should be performed before resection. The main concern in these patients is their pulmonary reserve and quality of life after undergoing operation on their only lung. Not all patients who present with a new lesion in the contralateral lung after pneumonectomy are candidates for resection. Only 3% of patients who had a pneumonectomy for lung cancer at our institution went on to subsequent resection during a 21-year period. Median forced expiratory volume in 1 second in our select group of patients was 1.47 L, with a range of 0.66 to 2.55L; only 2 patients had a forced expiratory volume in 1 second of less than 800 ml. Unfortunately, one of these patients died postoperatively, but not because of respiratory failure. The extent of pulmonary resection a patient can tolerate is determined preoperatively on the basis of both underlying pulmonary function and the patient s performance status. The size and the location of the lesion are also helpful in determining how much lung parenchyma will be removed with complete resection of the tumor. The need for a lobectomy to resect a deepseated tumor may be a limiting factor that prevents a patient from undergoing a potentially curative resection. Success of pulmonary resection in a patient who has had a previous pneumonectomy is dependent on a team approach consisting of an experienced thoracic surgeon, anesthesiologist, pulmonologist, respiratory therapist, dedicated nursing staff, and pulmonary rehabilitation specialists. New techniques in anesthesiology and critical care have enabled patients with poor pulmonary function to achieve a better outcome after pulmonary resection. Anesthetic agents with minimal respiratory and cardiac depression have led to early extubation, which avoids tracheobronchitis and nosocomial infections from prolonged mechanical ventilation. In our series, 92% of our patients were extubated by the morning after the procedure. Epidural anesthesia has helped to reduce postoperative pain and to enable patients to clear secretions by improved cough, deeper inspiration, and early ambulation. Also, because of the localized pain control there are fewer sedation problems, which allows patients to participate in an inpatient pulmonary rehabilitation program. Extended pulmonary resections, such as lobectomy, segmentectomy, and multiple wedge excisions, have been associated with a poor outcome in patients undergoing pulmonary resection after pneumonectomy [10, 13, 14]. This was also evident in our study. Postoperative respiratory function is dependent on the extent of resection and restrictive effect of the thoracotomy [21]. Also, manipulation and contusion of the residual lung may significantly impair the already limited pulmonary reserve in these patients. Therefore, resection should be performed using decreased tidal volumes to minimize barotrauma and parenchymal damage related to extensive manipulation of a hyperinflated lung. Periods of apnea are also frequently used to facilitate deeper wedge excisions and more extensive procedures. More than 40% of our patients had a more extensive procedure. Although preoperative risk factors were similar between the patients undergoing a more extensive resection and those undergoing a solitary wedge excision, the patients undergoing an extended resection had significantly more respiratory complications. Although lobectomy is considered the treatment of choice for early stage non small cell lung cancer because of less recurrence and improved survival compared with limited resection [22, 23], it is not usually an option for most patients after pneumonectomy, unless the middle lobe is the lobe considered for resection. Only 1 patient (4.2%) in our series had a lobectomy performed. Overall survival was not significantly influenced by limited resection in this select group of patients. Actually, patients who underwent a solitary wedge excision had a better 5-year survival than the patients who had a more extensive resection. When considering both the technical and oncologic aspects in this high-risk group of patients, limited resection provides the best risk-benefit ratio. A solitary wedge excision when possible should be consid-
5 158 DONINGTON ET AL Ann Thorac Surg PULMONARY RESECTION AFTER PNEUMONECTOMY 2002;74:154 9 ered the gold standard for patients with a lung cancer in the remaining lung. Because of limited cardiopulmonary reserve after pneumonectomy, one has to carefully evaluate the riskbenefit ratio of an additional resection in patients with metastatic disease. Our study showed that patients who underwent resection for metachronous cancer had an improved 5-year survival compared with patients who had resection for metastatic disease. Five-year survival after resection for metastatic disease was 14%. The problem is that one cannot differentiate whether the lesion is a metastatic tumor or a metachronous primary cancer until pathologic confirmation at the time of the thoracotomy. If the diagnosis of metastatic disease can be established preoperatively, other treatment modalities may be warranted. In conclusion, pulmonary resection of bronchogenic carcinoma after pneumonectomy is associated with acceptable morbidity and mortality. Long-term survival can be achieved in selected patients, especially in patients with a metachronous primary cancer. Wedge excision when feasible is the treatment of choice. References 1. Deschamps C, Pairolero PC, Trasteck VF, et al. Multiple primary lung cancers. J Thorac Cardiovasc Surg 1990;99: Fontana RS, Sanderson DR, Woolner LB, et al. Lung cancer screening: The Mayo program. J Occup Environ Med 1986; 28: Pairolero PC, Williams DE, Bergstralh EJ, et al. Postsurgical stage I bronchogenic carcinoma: morbid implications of recurrent disease. Ann Thorac Surg 1984;38: Fleisher AG, McElvaney G, Robinson CLN. Multiple primary bronchogenic carcinomas: treatment and follow-up. Ann Thorac Surg 1991;51: Martini N, Melamed M. Multiple primary lung cancers. J Thorac Cardiovasc Surg 1975;70: Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53: Shields TW, Drake CT, Sherick JC. Bilateral primary bronchogenic carcinoma. J Thorac Cardiovasc Surg 1964;48: Salerno TA, Munro DD, Blundell PE, et al. Second primary bronchogenic carcinoma: life-table analysis of surgical treatment. Ann Thorac Surg 1979;27: Kittle CF, Faber LP, Jensik RJ, et al. Pulmonary resection in patients after pneumonectomy. Ann Thorac Surg 1985;40: Levasseur P, Regnard JF, Icard P, et al. Cancer surgery on a single residual lung. Eur J Cardiothorac Surg 1992;6: Westermann CJ, van Swieten HA, Brutel de la Riviere A, et al. Pulmonary resections after pneumonectomy in patients with bronchogenic carcinoma. J Thorac Cardiovasc Surg 1993;106: Massard G, Wihlm JM, Monard G. Surgical management for metachronous bronchogenic carcinoma after pneumonectomy. J Thorac Cardiovasc Surg 1995;109: Spraggiari L, Grunenwald D, Girard P, et al. Cancer resection on the residual lung after pneumonectomy for bronchogenic carcinoma. Ann Thorac Surg 1996;62: Terzi A, Furlan G, Gorla A, et al. Lung resection on single residual lung after pneumonectomy for bronchogenic carcinoma. Thorac Cardiovasc Surg 1997;45: Mathisen DJ, Jensik RJ, Faber LP, et al. Survival following resection for second and third primary lung cancers. J Thorac Cardiovasc Surg 1984;88: Abbey-Smith R, Nigam BK, et al. Second primary lung cancer carcinoma. Thorax 1976;31: Jensik RJ, Faber LP. Kittle CF. Survival following resection for second primary bronchogenic carcinoma. J Thorac Cardiovasc Surg 1981;82: Hiebert CA. The cured lung cancer patient: is follow up by the surgeon worthwhile? Ann Thorac Surg 1991;60: Naunheim KS, Virgo KS. Postoperative surveillance following lung cancer resection. Chest Surg Clinic North Am 2001; 11: Midthun DE, Jett JR. Early detection of lung cancer: today s approach. J Respir Dis 1998;19: Cerfolio RJ, Allen MS, Trastek VF, et al. Lung resection in patients with compromised pulmonary function. Ann Thorac Surg 1996;62: Lung Cancer Study Group (prepared by Ginsberg RJ and Rubinstein LV). Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Ann Thorac Surg 1995;60: Miller DL, Rowland CM, Deschamps C, et al. Surgical treatment of non-small cell lung cancer one centimeter or less in diameter. Ann Thorac Surg 2002, in press. DISCUSSION DR LESLIE J. KOHMAN (Syracuse, NY): Very nicely presented. I have three questions. You had 24 patients of 700 some who had pneumonectomies. How many patients came back with a metachronous lung cancer and were turned down? You had all diffusing capacities greater than 50%, so this was obviously selected. I am just curious as to what percent of these patients actually did get into the surgeon s hands. The second question is, the patient who had a lobectomy, which lobe was it? The third question is how did you determine whether a tumor on the other side was a metastasis or a metachronous lung cancer of the same cell type? DR DONINGTON: I will start with the first one, which is we do not know the denominator in this group of patients. I cannot tell you how many of those 772 came back for evaluation and what percentage this 24 represents. The one lobe that was resected was a left lower lobe in a patient with a previous right pneumonectomy. As regards our criteria for a metachronous versus a primary lung cancer, we used the criteria as described by Doctor Martini in his article from 1975, which stated that a second tumor in a patient with a previous lung cancer would be a metachronous primary lung cancer and not a metastasis, one, if the histologies were different, or, two, if the interval between the two lesions was greater than 24 months with no evidence of distant metastatic disease. DR THOMAS R. TODD (Abu Dhabi, United Arab Emirates): I would like to follow up on what Leslie said. She noted that your diffusing capacities were high at 65, so this is probably a selected group of patients. Nonetheless, you do have forced expiratory volumes in 1 second as low as Did you report your data in your manuscript with the forced expiratory volume in 1 second being a percent of the forced vital capacity so that the number is a little more meaningful? Second, given the fact that we have
6 Ann Thorac Surg DONINGTON ET AL 2002;74:154 9 PULMONARY RESECTION AFTER PNEUMONECTOMY 159 learned from the lung volume reduction literature that the absolute forced expiratory volume in 1 second probably does not play a big role in the kind of operation that we perform, did you assess these people with either exercise testing or quantitative ventilation-perfusion scans to determine the function of the specific areas of lung you were going to resect? DR DONINGTON: As for your first question, yes, in the paper we present both the absolute volumes and the percents. As for exercise testing, yes, there actually was very good exercise testing documented in the majority of the charts on these patients, and they were not quantitative ventilation-perfusion scans but something a little more simple, as in most of the patients were walked up a flight of stairs or two. DR LARRY R. KAISER (Philadelphia, PA): Jessica, you mentioned staging the mediastinum. Your conclude that a wedge excision is adequate yet you did at least perform lymph node sampling or lymph node dissection in some of these patients. Do you stage these patients preoperatively? Would you recommend performing mediastinoscopy on these patients? If you did mediastinoscopy and found N2 disease, would you still recommend a resection in that particular patient? Is it feasible to do mediastinoscopy in these patients? Were all of these pneumonectomies performed at your institution or were some of these from outside and thus your denominator is a little bit misleading? DR DONINGTON: Three of the procedures were performed at an outside institution. Not all the patients had had a mediastinoscopy either at the initial or at the second resection. We would recommend staging the mediastinum and the patients as carefully as possible, including, obviously, chest computed tomography and probably positron emission tomography scan in all patients. We did not perform mediastinoscopy before any of these procedures, but we do not consider that as something that could not be done in a suspicious mediastinum. DR ROBERT J. CERFOLIO (Birmingham, AL): I have a question about the lymph nodes, I thought Doctor Kaiser was going to ask that, but he did not go where I thought he was going to go. I notice that you did not stage 12 patients, ie, 12 patients do not have their lymph nodes removed and were not adequately staged. I know that the Mayo Clinic preaches and practices outstanding staging having been there and been trained by Doctors Pairolero, Allen, Deschamps, and Trastek, most of you perform a complete thoracic lymphadenectomy, as I currently do now at University of Alabama Brimingham. Was the decision not to remove the nodes intentionally made because of the fear of pulmonary edema? For example, if the initial pneumonectomy was performed and the patient had a complete thoracic lymphadenectomy on one side, did you think it was contraindicated to do another thoracic lymphadenectomy because of some of the reports of pulmonary edema; is that why you did not stage these 12 patients? If so can you elaborate on that phenomenon, its incidence, and treatment and prevention. It seems very unusual to me that the patients did not have some type of intraoperative lymph nodes staging performed at least a biopsy of each nodal station. Was this done intentionally to avoid complications from bilateral thoracic lymphadenectomy? DR DONINGTON: I do not believe so. The one thing I can tell you about the lymphadenectomies is that the timing of them is a very long retrospective review. Many of the older subsequent resections did not have lymph node dissections that went along with them. Many of the more recent ones did. So I think that there has probably been a change in the philosophy at the institution. DR RICHARD I. WHYTE (Stanford, CA): Jessica, I enjoyed your presentation. I found it very interesting. At the end you make the conclusion that it is justifiable to do these operations on certain individuals with recurrent lung cancer. My question is, are you including in the term recurrent both the metastatic as well as the metachronous lesions? When you look at the metastatic tumors, you quoted a 5-year survival rate of 14%. Actually the data showed it to be a 3.5-year survival rate of 14%. So you actually observed not a very good survival for some of these patients, and perhaps some alternative measures should be considered instead of operating on these highrisk individuals. DR DONINGTON: We agree, but the one thing that we have to note is that until you operate, you do not always necessarily know whether this is a metachronous lung cancer or a metastatic disease. Even many patients who had a short, what we would call disease-free, interval, when we went back the second time, it was actually a different histology and therefore a different lung cancer.
Complete surgical excision remains the greatest potential
ORIGINAL ARTICLE Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD,* Charles E. Eastridge, MD, Elizabeth A. Tolley,
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/23566
More informationLung Cancer in Octogenarians: Factors Affecting Morbidity and Mortality After Pulmonary Resection
ORIGINAL ARTICLES: SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article, you must have either an STS
More informationM expected to arise in 1.6% to 3.0% of all patients. Multiple Primary Lung Carcinomas: Prognosis and Treatment
Multiple Primary Lung Carcinomas: Prognosis and Treatment Todd K. Rosengart, MD, Nael Martini, MD, Pierre Ghosn, MD, and Michael Burt, MD, PhD Thoracic Service, Department of Surgery, Memorial-Sloan Kettering
More information141 Ann Thorac Surg , Aug Copyright by The Society of Thoracic Surgeons
Completion Pneumonectomy: Indications, Complications, and Results Eilis M. McGovern, M.B.B.Ch., Victor F. Trastek, M.D., Peter C. Pairolero, M.D., and W. Spencer Payne, M.D. ABSTRACT From 958 through 985,
More informationMarcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD; and Jules M. M. van den Bosch, MD, PhD, FCCP
Prognostic Assessment of 2,361 Patients Who Underwent Pulmonary Resection for Non-small Cell Lung Cancer, Stage I, II, and IIIA* Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans
More informationMEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER
MEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Hideki Akamatsu, MD a Yuzo
More informationAlthough the international TNM classification system
Prognostic Significance of Perioperative Serum Carcinoembryonic Antigen in Non-Small Cell Lung Cancer: Analysis of 1,000 Consecutive Resections for Clinical Stage I Disease Morihito Okada, MD, PhD, Wataru
More informationThoracic Surgery; An Overview
Thoracic Surgery What we see Thoracic Surgery; An Overview James P. Locher, Jr, MD Methodist Cardiovascular and Thoracic Surgery Lung cancer Mets Fungus and TB Lung abcess and empyema Pleural based disease
More informationLYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG
LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Takehiro Watanabe, MD a Yuzo Kurita, MD b Akira Yokoyama, MD b Keiichi
More informationBronchogenic Carcinoma
A 55-year-old construction worker has smoked 2 packs of ciggarettes daily for the past 25 years. He notes swelling in his upper extremity & face, along with dilated veins in this region. What is the most
More informationTreatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard
Treatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard AATS General Thoracic Surgery Symposium May 5, 2010 Thomas A. D Amico MD Professor of Surgery, Duke University Medical
More informationPAPER. See Invited Critique at end of article
PAPER Systematic Postoperative Radiologic Follow-up in Patients With Non Small Cell Lung Cancer for Detecting Second Primary Lung Cancer in Stage IA Jeffrey P. Lamont, MD; James T. Kakuda, MD; David Smith,
More informationPreoperative Workup for Pulmonary Resection. Kristen Bridges, M.D. Richmond University Medical Center January 21, 2016
Preoperative Workup for Pulmonary Resection Kristen Bridges, M.D. Richmond University Medical Center January 21, 2016 Patient Presentation 50 yo male with 70 pack year smoking history Large R hilar lung
More informationThe right middle lobe is the smallest lobe in the lung, and
ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,
More informationAdam J. Hansen, MD UHC Thoracic Surgery
Adam J. Hansen, MD UHC Thoracic Surgery Sometimes seen on Chest X-ray (CXR) Common incidental findings on computed tomography (CT) chest and abdomen done for other reasons Most lung cancers discovered
More informationCharles Mulligan, MD, FACS, FCCP 26 March 2015
Charles Mulligan, MD, FACS, FCCP 26 March 2015 Review lung cancer statistics Review the risk factors Discuss presentation and staging Discuss treatment options and outcomes Discuss the status of screening
More informationSuperior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis
ORIGINAL ARTICLES: Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis Shun-ichi Watanabe, MD, Kenji Suzuki, MD, and Hisao Asamura, MD
More informationTreatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer
Treatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer Ryoichi Nakanishi, MD, Toshihiro Osaki, MD, Kozo Nakanishi, MD, Ichiro Yoshino, MD, Takashi Yoshimatsu,
More informationNon-Small Cell Lung Cancer: Disease Spectrum and Management in a Tertiary Care Hospital
Non-Small Cell Lung Cancer: Disease Spectrum and Management in a Tertiary Care Hospital Muhammad Rizwan Khan,Sulaiman B. Hasan,Shahid A. Sami ( Department of Surgery, The Aga Khan University Hospital,
More informationSurgery for early stage NSCLC
1-3 March 2017, Manchester, UK Surgery for early stage NSCLC Dominique H. Grunenwald, MD, PhD Professor Emeritus in Thoracic and Cardiovascular surgery Pierre & Marie Curie University. Paris. France what
More informationAfter primary tumor treatment, 30% of patients with malignant
ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant
More informationCarcinoma of the Lung
THE ANNALS OF THORACIC SURGERY Journal of The Society of Thoracic Surgeons and the Southern Thoracic Surgical Association VOLUME 1 I - NUMBER 3 0 MARCH 1971 Carcinoma of the Lung M. L. Dillon, M.D., and
More informationSlide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology
Slide 1 Investigation and management of lung cancer Robert Rintoul Department of Thoracic Oncology Papworth Hospital Slide 2 Epidemiology Second most common cancer in the UK (after breast). 38 000 new
More informationPulmonary resection remains the most effective. Survival in Synchronous vs Single Lung Cancer. Upstaging Better Reflects Prognosis
Survival in Synchronous vs Single Lung Cancer Upstaging Better Reflects Prognosis Marcel Th. M. van Rens, MD; Pieter Zanen, MD, PhD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD;
More informationSite of Recurrence in Patients. of the Lung Resected for Cure. with Stages I and I1 Carcinoma
Site of Recurrence in Patients with Stages I and I1 Carcinoma of the Lung Resected for Cure Steven C. Immerman, M.D., Robert M. Vanecko, M.D., Willard A. Fry, M.D., Louis R. Head, M.D., and Thomas W. Shields,
More informationThe roles of adjuvant chemotherapy and thoracic irradiation
Factors Predicting Patterns of Recurrence After Resection of N1 Non-Small Cell Lung Carcinoma Timothy E. Sawyer, MD, James A. Bonner, MD, Perry M. Gould, MD, Robert L. Foote, MD, Claude Deschamps, MD,
More informationOncologic Efficacy of Anatomic Segmentectomy in Stage IA Lung Cancer Patients With T1a Tumors
Oncologic Efficacy of Anatomic Segmentectomy in Stage IA Lung Cancer Patients With T1a Tumors James M. Donahue, MD, Christopher R. Morse, MD, Dennis A. Wigle, MD, PhD, Mark S. Allen, MD, Francis C. Nichols,
More informationand Strength of Recommendations
ASTRO with ASCO Qualifying Statements in Bold Italics s patients with T1-2, N0 non-small cell lung cancer who are medically operable? 1A: Patients with stage I NSCLC should be evaluated by a thoracic surgeon,
More informationD tion therapy, complete resection of a tumor offers
Determinants of Perioperative Morbidity and Mortality After Pneumonectomy Rakesh Wahi, MBBS, Marion J. McMurtrey, MD, Louis F. DeCaro, MD, Clifton F. Mountain, MD, Mohamed K. Ali, MD, Terry L. Smith, MS,
More informationDespite their reputation of benignity, carcinoid tumors
Operative Risk and Prognostic Factors of Typical Bronchial Carcinoid Tumors Xavier Ducrocq, MD, Pascal Thomas, MD, Gilbert Massard, MD, Pierre Barsotti, MD, Roger Giudicelli, MD, Pierre Fuentes, MD, and
More informationRelevance of an Intensive Postoperative Follow-up After Surgery for Non Small Cell Lung Cancer
Relevance of an Intensive Postoperative Follow-up After Surgery for Non Small Cell Lung Cancer Virginie Westeel, MD, Didier Choma, MD, François Clément, MD, Marie-Christine Woronoff-Lemsi, PhD, Jean-François
More informationCompletion pneumonectomy for lung cancer
Journal of BUON 7: 235-240, 2002 2002 Zerbinis Medical Publications. Printed in Greece ORIGINAL ARTICLE Completion pneumonectomy for lung cancer N. Baltayiannis, D. Anagnostopoulos, N. Bolanos, L. Tsourelis
More informationPrapaporn Pornsuriyasak, M.D. Pulmonary and Critical Care Medicine Ramathibodi Hospital
Prapaporn Pornsuriyasak, M.D. Pulmonary and Critical Care Medicine Ramathibodi Hospital Only 20-30% of patients with lung cancer are potential candidates for lung resection Poor lung function alone ruled
More informationShort- and Long-Term Outcomes after Pneumonectomy for Primary Lung Cancer
Original Article Short- and Long-Term Outcomes after Pneumonectomy for Primary Lung Cancer Takeshi Kawaguchi, MD, Takashi Tojo, MD, Keiji Kushibe, MD, Michitaka Kimura, MD, Yoko Nagata, MD, and Shigeki
More informationThe tumor, node, metastasis (TNM) staging system of lung
ORIGINAL ARTICLE Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease Hao-Xian Yang, MD, PhD,* Xue Hou, MD, Peng Lin,
More informationTHORACIC MALIGNANCIES
THORACIC MALIGNANCIES Summary for Malignant Malignancies. Lung Ca 1 Lung Cancer Non-Small Cell Lung Cancer Diagnostic Evaluation for Non-Small Lung Cancer 1. History and Physical examination. 2. CBCDE,
More informationSegmentectomy versus lobectomy in patients with stage I pulmonary carcinoma
Segmentectomy versus lobectomy in patients with stage pulmonary carcinoma Five-year survival and patterns of intrathoracic recurrence One hundred seventy-three patients with stage (Tl NO, T2 NO) non-small-cell
More informationTreatment of oligometastatic NSCLC
Treatment of oligometastatic NSCLC Jarosław Kużdżał Department of Thoracic Surgery Jagiellonian University Collegium Medicum, John Paul II Hospital, Cracow New idea? 14 NSCLC patients with solitary extrathoracic
More informationCASE REPORT. Introduction. Case series reports. J Thorac Dis 2012;4(S1): DOI: /j.issn s003
CASE REPORT Lost in time pulmonary metastases of renal cell carcinoma: complete surgical resection of metachronous metastases, 18 and 15 years after nephrectomy Kosmas Tsakiridis 1, Aikaterini N Visouli
More informationValue of Systematic Mediastinal Lymph Node Dissection During Pulmonary Metastasectomy
Value of Systematic Mediastinal Lymph Node Dissection During Pulmonary Metastasectomy Florian Loehe, MD, Sonja Kobinger, MD, Rudolf A. Hatz, MD, Thomas Helmberger, MD, Udo Loehrs, MD, and Heinrich Fuerst,
More informationStandard treatment for pulmonary metastasis of non-small
ORIGINAL ARTICLE Resection of Pulmonary Metastasis of Non-small Cell Lung Cancer Kenichi Okubo, MD,* Toru Bando, MD,* Ryo Miyahara, MD,* Hiroaki Sakai, MD,* Tsuyoshi Shoji, MD,* Makoto Sonobe, MD,* Takuji
More informationT3 NSCLC: Chest Wall, Diaphragm, Mediastinum
for T3 NSCLC: Chest Wall, Diaphragm, Mediastinum AATS Postgraduate Course April 29, 2012 Thomas A. D Amico MD Professor of Surgery, Chief of Thoracic Surgery Duke University Health System Disclosure No
More informationORIGINAL PAPER. Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery
Nagoya J. Med. Sci. 79. 37 ~ 42, 2017 doi:10.18999/nagjms.79.1.37 ORIGINAL PAPER Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery Naoki Ozeki, Koji
More informationIncidence of local recurrence and second primary tumors in resected stage I lung cancer
Incidence of local recurrence and second primary tumors in resected stage I lung cancer From 1973 to 1985, 598 patients underwent resection for stage I non-small-cell lung cancer. There were 291 T1 lesions
More informationSignificance of Metastatic Disease
Significance of Metastatic Disease in Subaortic Lymph Nodes G. A. Patterson, M.D., D. Piazza, M.D., F. G. Pearson, M.D., T. R. J. Todd, M.D., R. J. Ginsberg, M.D., M. Goldberg, M.D., P. Waters, M.D., D.
More informationRevisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis
Jpn J Clin Oncol 1997;27(5)305 309 Revisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis -, -, - - 1 Chest Department and 2 Section of Thoracic Surgery,
More informationThe Importance of One-Stage Median Stemotomy and Retroperitoneal Node Dissection in Disseminated Testicular Cancer
The Importance of One-Stage Median Stemotomy and Retroperitoneal Node Dissection in Disseminated Testicular Cancer Isidore Mandelbaum, M.D., Peter B. Yaw, M.D., Lawrence H. Einhorn, M.D., Stephen D. Williams,
More informationIn 1989, Deslauriers et al. 1 described intrapulmonary metastasis
ORIGINAL ARTICLE Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD,* Yasunori Sohara, MD, Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, and Etsuo Miyaoka,
More informationLarry Tan, MD Thoracic Surgery, HSC. Community Cancer Care Educational Conference October 27, 2017
Larry Tan, MD Thoracic Surgery, HSC Community Cancer Care Educational Conference October 27, 2017 To describe patient referral & triage for the patient with suspected lung cancer To describe the initial
More informationLung Cancer Clinical Guidelines: Surgery
Lung Cancer Clinical Guidelines: Surgery 1 Scope of guidelines All Trusts within Manchester Cancer are expected to follow this guideline. This guideline is relevant to: Adults (18 years and older) with
More informationLung Cancer Resection
Lung Cancer Resection Introduction The occurrence of lung cancer has increased dramatically over the last 50 years. Your health care provider may have recommended an operation to remove your lung cancer.
More informationThe Role of Radiation Therapy
The Role of Radiation Therapy and Surgery in the Treatment of Bronchogenic Carcinoma R Adams Cowley, M.D., Morris J. Wizenberg, M.D., and Eugene J. Linberg, M.D. A study of the combined use of preoperative
More informationSurgical Treatment of Metachronous Nonsmall Cell Lung Cancer
Original Article Surgical Treatment of Metachronous Nonsmall Cell Lung Cancer Shuji Haraguchi, MD, 1,2 Kiyoshi Koizumi, MD, 1,2 Tomomi Hirata, MD, 1,2 Kyoji Hirai, MD, 1,2 Iwao Mikami, MD, 1,2 Hirotoshi
More informationCarcinoma of the Lung in Women
Carcinoma of the Lung in Marvin M. Kirsh, M.D., Jeanne Tashian, M.A., and Herbert Sloan, M.D. ABSTRACT The 5-year survival of 293 men and of 78 women undergoing pulmonary resection and mediastinal lymph
More informationChirurgie beim oligo-metastatischen NSCLC
24. Ärzte-Fortbildungskurs in Klinischer Onkologie 20.-22. Februar 2014, Kantonsspital St. Gallen Chirurgie beim oligo-metastatischen NSCLC Prof. Dr. med. Walter Weder Klinikdirektor Thoraxchirurgie, UniversitätsSpital
More informationAggressive Slurgical Management of Testicular Carcinoma Metastatic to Lungs and Mediastinurn
Aggressive Slurgical Management of Testicular Carcinoma Metastatic to Lungs and Mediastinurn Isadore Mandelbaum, M.D., Stephen D. Williams, M.D., and Lawrence H. Einhorn, M.D. ABSTRACT During the past
More informationRole of Surgery in Management of Non Small Cell Lung Cancer. Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City
Role of Surgery in Management of Non Small Cell Lung Cancer Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City Introduction Surgical approach Principle and type of surgery
More informationProper Treatment Selection May Improve Survival in Patients With Clinical Early-Stage Nonsmall Cell Lung Cancer
Proper Treatment Selection May Improve Survival in Patients With Clinical Early-Stage Nonsmall Cell Lung Cancer Özcan Birim, MD, A. Pieter Kappetein, MD, PhD, Tom Goorden, MD, Rob J. van Klaveren, MD,
More informationPulmonary Resection for Metastases from Colorectal Cancer
ORIGINAL ARTICLE Pulmonary Resection for Metastases from Colorectal Cancer Paul M. van Schaik, MD,* Ewout A. Kouwenhoven, MD, PhD,* Robert J. Bolhuis, MD,* Bonne Biesma, MD, PhD, and Koop Bosscha, MD,
More informationLung Cancer. Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD
Lung Cancer Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD Objectives Describe risk factors, early detection & work-up of lung cancer. Define the role of modern treatment options, minimally invasive
More informationLymph node dissection for lung cancer is both an old
LOBE-SPECIFIC EXTENT OF SYSTEMATIC LYMPH NODE DISSECTION FOR NON SMALL CELL LUNG CARCINOMAS ACCORDING TO A RETROSPECTIVE STUDY OF METASTASIS AND PROGNOSIS Hisao Asamura, MD Haruhiko Nakayama, MD Haruhiko
More informationPrognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai, China
www.springerlink.com Chin J Cancer Res 23(4):265 270, 2011 265 Original Article Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai,
More informationIdiopathic pulmonary fibrosis (IPF), also referred to as
Operation for Lung Cancer in Patients With Idiopathic Pulmonary Fibrosis: Surgical Contraindication? Toshio Fujimoto, MD, Tsuyoshi Okazaki, MD, Tadashi Matsukura, MD, Takeshi Hanawa, MD, Naoki Yamashita,
More informationTracheal Adenocarcinoma Treated with Adjuvant Radiation: A Case Report and Literature Review
Published online: May 23, 2013 1662 6575/13/0062 0280$38.00/0 This is an Open Access article licensed under the terms of the Creative Commons Attribution- NonCommercial-NoDerivs 3.0 License (www.karger.com/oa-license),
More informationcame from a carcinoma and in 12 from a sarcoma. Ninety lesions were intrapulmonary and the as the chest wall and pleura. Details of the primary
Thorax 1982;37:366-370 Thoracic metastases MARY P SHEPHERD From the Thoracic Surgical Unit, Harefield Hospital, Harefield ABSTRACI One hundred and four patients are reviewed who were found to have thoracic
More informationPulmonary resection for metastatic colorectal carcinoma was first performed
General Thoracic Surgery Pulmonary metastasectomy for 165 patients with colorectal carcinoma: A prognostic assessment Yukihito Saito, MD, a Hideyasu Omiya, MD, a Keijiro Kohno, MD, b Takanobu Kobayashi,
More informationAlthough air leaks continue to be one of the most
ORIGINAL ARTICLES: GENERAL THORACIC Prospective Randomized Trial Compares Suction Versus Water Seal for Air Leaks Robert J. Cerfolio, MD, Cyndi Bass, MSN, CRNP, and Charles R. Katholi, PhD Department of
More informationMultifocal Lung Cancer
Multifocal Lung Cancer P. De Leyn, MD, PhD Department of Thoracic Surgery University Hospitals Leuven Belgium LEUVEN LUNG CANCER GROUP Department of Thoracic Surgery Department of Pneumology Department
More informationMediastinal Staging. Samer Kanaan, M.D.
Mediastinal Staging Samer Kanaan, M.D. Overview Importance of accurate nodal staging Accuracy of radiographic staging Mediastinoscopy EUS EBUS Staging TNM Definitions T Stage Size of the Primary Tumor
More informationP sumed to have early lung disease with a favorable
Survival After Resection of Stage I1 Non-Small Cell Lung Cancer Nael Martini, MD, Michael E. Burt, MD, PhD, Manjit S. Bains, MD, Patricia M. McCormack, MD, Valerie W. Rusch, MD, and Robert J. Ginsberg,
More informationPET/CT in lung cancer
PET/CT in lung cancer Andrei Šamarin North Estonia Medical Centre 3 rd Baltic Congress of Radiology 08.10.2010 Imaging in lung cancer Why do we need PET/CT? CT is routine imaging modality for staging of
More informationFariba Rezaeetalab Associate Professor,Pulmonologist
Fariba Rezaeetalab Associate Professor,Pulmonologist rezaitalabf@mums.ac.ir Patient related risk factors Procedure related risk factors Preoperative risk assessment Risk reduction strategies Age Obesity
More informationPredicting Postoperative Pulmonary Function in Patients Undergoing Lung Resection*
Predicting Postoperative Pulmonary Function in Patients Undergoing Lung Resection* Bernhardt G. Zeiher, MD; Thomas ]. Gross, MD; Jeffery A. Kern, MD, FCCP; Louis A. Lanza, MD, FCCP; and Michael W. Peterson,
More informationAlthough ipsilateral intrapulmonary metastasis (PM), Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis
Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis Morihito Okada, MD, Noriaki Tsubota, MD, Masahiro Yoshimura, MD, Yoshifumi Miyamoto, MD, and Reiko Nakai,
More informationEarly and locally advanced non-small-cell lung cancer (NSCLC)
Early and locally advanced non-small-cell lung cancer (NSCLC) ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up P. E. Postmus, K. M. Kerr, M. Oudkerk, S. Senan, D. A. Waller, J.
More informationThe Value of Adjuvant Radiotherapy in Pulmonary and Chest Wall Resection for Bronchogenic Carcinoma
The Value of Adjuvant Radiotherapy in Pulmonary and Chest Wall Resection for Bronchogenic Carcinoma G. A. Patterson, M.D., R. Ilves, M.D., R. J. Ginsberg, M.D., J. D. Cooper, M.D., T. R. J. Todd, M.D.,
More informationLobectomy Versus Sublobar Resection for Small (2 cm or Less) Non Small Cell Lung Cancers
Lobectomy Versus Resection for Small (2 cm or Less) Non Small Cell Lung Cancers Andrea S. Wolf, MD, William G. Richards, PhD, Michael T. Jaklitsch, MD, Ritu Gill, MD, Lucian R. Chirieac, MD, Yolonda L.
More informationThoracoscopic Lobectomy for Locally Advanced Lung Cancer. Masters of Minimally Invasive Thoracic Surgery Orlando September 19, 2014
for Locally Advanced Lung Cancer Masters of Minimally Invasive Thoracic Surgery Orlando September 19, 2014 Thomas A. D Amico MD Gary Hock Endowed Professor and Vice Chair of Surgery Chief Thoracic Surgery
More informationLung Cancer-a primer. Sai Yendamuri, MD Professor and Chair, Dept of Thoracic Surgery,RPCI,Buffalo
Lung Cancer-a primer Sai Yendamuri, MD Professor and Chair, Dept of Thoracic Surgery,RPCI,Buffalo CLINICAL CATEGORIES THE SOLITARY PULMONARY NODULE MULTIPLE PULMONARY NODULES Differential Diagnosis Malignant
More informationExpert Round Table with Drs. Anne Tsao and Alex Farivar Part 1: Elderly Man with Indolent Bronchioloalveolar Carcinoma
Expert Round Table with Drs. Anne Tsao and Alex Farivar Part 1: Elderly Man with Indolent Bronchioloalveolar Carcinoma February 2010 I d like to welcome everyone, thanks for coming out to our lunch with
More informationMediastinal Spread of Metastatic Lymph Nodes in Bronchogenic Carcinoma*
Mediastinal Spread of Metastatic Lymph Nodes in Bronchogenic Carcinoma* Mediastinal Nodal Metastases in Lung Cancer Yoh Watanabe, M.D., F.C.C.P.; ]unzo Shimizu, M.D.; Makoto Tsubota, M.D.; and Takashi
More informationThoracoscopy for Lung Cancer
Thoracoscopy for Lung Cancer Introduction The occurrence of lung cancer has increased dramatically over the last 50 years. Your doctor may have recommended an operation to remove your lung cancer. The
More informationComplex Thoracoscopic Resections for Locally Advanced Lung Cancer
Complex Thoracoscopic Resections for Locally Advanced Lung Cancer Duke Thoracoscopic Lobectomy Workshop March 21, 2018 Thomas A. D Amico MD Gary Hock Professor of Surgery Section Chief, Thoracic Surgery,
More informationClinical results of sublobar resection versus lobectomy or more extensive resection for lung cancer patients with idiopathic pulmonary fibrosis
Original Article Clinical results of sublobar resection versus lobectomy or more extensive resection for lung cancer patients with idiopathic pulmonary fibrosis Seok Joo 1, Dong Kwan Kim 2, Hee Je Sim
More informationCase Scenario 1. The patient agreed to a CT guided biopsy of the left upper lobe mass. This was performed and confirmed non-small cell carcinoma.
Case Scenario 1 An 89 year old male patient presented with a progressive cough for approximately six weeks for which he received approximately three rounds of antibiotic therapy without response. A chest
More informationMolly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010
LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical
More informationCheng-Yang Song, Takehiro Sakai, Daisuke Kimura, Takao Tsushima, Ikuo Fukuda
Original Article Comparison of perioperative and oncological outcomes between video-assisted segmentectomy and lobectomy for patients with clinical stage IA non-small cell lung cancer: a propensity score
More informationIndex. Note: Page numbers of article titles are in boldface type
Index Note: Page numbers of article titles are in boldface type A Acute coronary syndrome, perioperative oxygen in, 599 600 Acute lung injury (ALI). See Lung injury and Acute respiratory distress syndrome.
More informationThe Itracacies of Staging Patients with Suspected Lung Cancer
The Itracacies of Staging Patients with Suspected Lung Cancer Gerard A. Silvestri, MD,MS, FCCP Professor of Medicine Medical University of South Carolina Charleston, SC silvestri@musc.edu Staging Lung
More informationISPUB.COM. Rare Cases: Tracheal/bronchial Obstruction. O Wenker, L Moehn, C Portera, G Walsh HISTORY ADMISSION
ISPUB.COM The Internet Journal of Radiology Volume 1 Number 1 O Wenker, L Moehn, C Portera, G Walsh Citation O Wenker, L Moehn, C Portera, G Walsh.. The Internet Journal of Radiology. 1999 Volume 1 Number
More informationSurgical treatment of synchronous multiple neuroendocrine lung tumours (case series): is more always better?
Case Report Page 1 of 5 Surgical treatment of synchronous multiple neuroendocrine lung tumours (case series): is more always better? Jury Brandolini, Luca Bertolaccini, Alessandro Pardolesi, Piergiorgio
More informationThoracic surgeons are seldom confronted with hematologic
Role of Surgery in the Treatment of Primary Pulmonary B-Cell Lymphoma Frederic Vanden Eynden, MD, Elie Fadel, MD, Marc de Perrot, MD, MS, Vincent de Montpreville, MD, Sacha Mussot, MD, and Philippe Dartevelle,
More informationSmall cell lung cancer (SCLC), which represents 20%
ORIGINAL ARTICLES: GENERAL THORACIC Surgical Results for Small Cell Lung Cancer Based on the New TNM Staging System Masayoshi Inoue, MD, Shinichiro Miyoshi, MD, Tsutomu Yasumitsu, MD, Takashi Mori, MD,
More informationTHORACIK RICK. Lungs. Outline and objectives Richard A. Malthaner MD MSc FRCSC FACS
THORACIK RICK Outline and objectives Lungs Management of a solitary lung nodule Mediastinum Management of a mediastinal mass Pleura Management of a pleural fluid & pneumothorax Esophagus & Stomach Management
More informationWhen a solitary pulmonary lesion (SPL) is found in
GENERAL THORACIC Resection of Solitary Pulmonary Lesion Is Beneficial to Patients With a History of Malignancy Miki Sakamoto, MD, Tomohiro Murakawa, MD, Kentaro Kitano, MD, Tomonori Murayama, MD, Takehiro
More informationLung cancer pleural invasion was recognized as a poor prognostic
Visceral pleural invasion classification in non small cell lung cancer: A proposal on the basis of outcome assessment Kimihiro Shimizu, MD a Junji Yoshida, MD a Kanji Nagai, MD a Mitsuyo Nishimura, MD
More informationIndications for sublobar resection for localized NSCLC
Indications for sublobar resection for localized NSCLC David H Harpole Jr, MD Professor of Surgery Associate Professor in Pathology Vice Chief, Division of Surgical Services Duke University School of Medicine
More informationA carcinoma of the lung reported by Graham and. Predicted Pulmonary Function and Survival After Pneumonectomy for Primary Lung Carcinoma
Predicted Pulmonary Function and Survival After Pneumonectomy for Primary Lung Carcinoma Joe B. Putnam, Jr, MD, David E. Lammermeier, MD, Rolando Colon, MD, Marion J. McMurtrey, MD, Mohammed K. Ali, MD,
More informationSatellite Pulmonary Nodule in the Same Lobe (T4N0) Should Not Be Staged as IIIB Non Small Cell Lung Cancer
Satellite Pulmonary Nodule in the Same Lobe (T4N0) Should Not Be Staged as IIIB Non Small Cell Lung Cancer Ayesha S. Bryant, MSPH, MD, Sara J. Pereira, MD, Daniel L. Miller, MD, and Robert James Cerfolio,
More information